J&J spins off orthopaedics business against positive Q3 backdrop
Johnson & Johnson (J&J) has made the latest slimming down move across its company in recent years, saying it plans …
Post
-
-
Kailera nets $600m to power Phase III launch of obesity drug
Just a year after emerging from stealth with a nearly half a billion dollars, Kailera Therapeutics has reached another financing …
-
China’s drugs offer lifeline for global pharma as it peers over the patent cliff
Out-licensing of clinical candidates from China has increased dramatically over the last five years, as the world’s pharma companies shore …
-
FDA approves AbbVie’s Rinvoq for inflammatory bowel disease
The US Food and Drug Administration (FDA) has approved AbbVie’s supplemental new drug application, updating the indication statement for Rinvoq …
-
From strategy to submission: How your CRO should create value beyond execution
Biopharma innovators are operating in an environment shaped by the medical need for new and advanced therapies, the sheer volume …
-
CIPO grants patent to Palisade Bio’s PALI-2108
The Canadian Intellectual Property Office (CIPO) has awarded Palisade Bio a patent for its ileocolonic-targeted Phosphodiesterase 4, subtype B/D (PDE4 …
-
Advanced bioconjugation strategies: New webinar tackles complex chemistry for targeted therapeutics
In the fast-paced environment of pharmaceutical innovation, bioconjugation has proved to be a cornerstone technology. By enabling the precise modification …
-
New US biotech hubs showing potential amid onshoring request
Ever since its early roots, the US has been a key player in the pharmaceutical industry, with prominent names like …
-
BIOSECURE returns to US pharma agenda with 2.0 update
After a year in the shadows, the controversial BIOSECURE Act could make a return following an endorsement of a revised …
-
AstraZeneca inks Trump drug pricing deal amid tariff threats
UK-Swedish pharmaceutical giant AstraZeneca has signed a drug pricing deal with the US government, becoming the second industry titan to …
-
J&J in talks to acquire Protagonist Therapeutics
Johnson & Johnson (J&J) is in discussions to purchase Protagonist Therapeutics, a move that would enhance their current collaboration, as …
-
FDA approves Teva and Medincell’s bipolar I disorder treatment
Teva Pharmaceuticals and Medincell have gained approval from the US Food and Drug Administration (FDA) for Uzedy (risperidone), a once-a-month …
-
FDA ‘green list’ flagging illegal GLP-1RA compounders is long overdue
In the midst of the rising popularity of glucagon-like peptide-1 receptor agonists (GLP-1RAs), and their compounded versions, the US Food …
-
Podcast: The FDA’s emerging aversion to advisory committees
Last month, the head of the US Food and Drug Administration's (FDA) Centre for Drug Evaluation and Research (CDER) George …
-
BMS expands CAR-T portfolio with $1.5bn Orbital buyout
Bristol Myers Squibb (BMS) has agreed to acquire CAR-T specialist Orbital Therapeutics for $1.5bn, adding several RNA-based therapies to the …
